Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Will Focus On Value, Not Price, Of Medicines, McClellan Pledges

Executive Summary

Medicare reimbursement should be based on the "value" of medicines, not their price, incoming Centers for Medicare & Medicaid Services Administrator Mark McClellan told the Senate Finance Committee in a 1written Q&A exchange

You may also be interested in...



Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling

Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness

Kaiser Permanente Clinical Trials Tool Includes Cost-Effectiveness Modeling

Kaiser Permanente is developing a clinical trials modeling tool that can also be used to estimate a drug's cost-effectiveness

CMS Says Medicare Rx Will Grow 7.5% Per Year; Challenge To Pharma?

The rate of per capita drug spending under the new Medicare Part D benefit will be half the current rate of prescription drug spending growth in the U.S., CMS predicts

Related Content

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel